论文部分内容阅读
目的:探讨扶正合剂联合化疗治疗晚期三阴性乳腺癌的临床疗效。方法:选取晚期三阴性乳腺癌患者60例,采用随机分组对照法,分为治疗组和对照组各30例,治疗组采用化疗+口服扶正合剂治疗,对照组仅采用化疗,治疗后评价两组患者的临床症状、生活质量、不良反应以及肿瘤标志物水平的变化。结果:在缩小瘤体方面,两组差异无统计学意义(P>0.05),但治疗组肿瘤控制率优于对照组,差异有统计学意义(P<0.05);两组患者在卡氏评分、临床症状改善方面,差异有统计学意义(P<0.01);治疗组不良反应发生率低于对照组,差异有统计学意义(P<0.05);在降低血清肿瘤标志物方面,两组治疗前后癌胚抗原(CEA)水平变化差异无统计学意义(P>0.05),血清糖蛋白抗原153水平(CA153)变化差异有统计学意义(P<0.05)。结论:扶正合剂联合化疗治疗晚期三阴性乳腺癌,可起到增效减毒的作用。
Objective: To investigate the clinical effect of Fuzheng Mixture combined with chemotherapy in the treatment of advanced triple-negative breast cancer. Methods: Sixty patients with advanced triple-negative breast cancer were enrolled in this study. They were randomly divided into control group and control group. The treatment group was treated with chemotherapy plus oral Fuzheng Mixture, the control group with chemotherapy alone, and the post-treatment evaluation with two groups Patient’s clinical symptoms, quality of life, adverse reactions, and changes in tumor marker levels. Results: There was no significant difference between the two groups in reducing tumor size (P> 0.05), but the tumor control rate in the treatment group was better than that in the control group (P <0.05). In the two groups, (P <0.01). The incidence of adverse reactions in the treatment group was lower than that in the control group, with significant difference (P <0.05). In reducing the serum tumor markers, the two groups of treatment There was no significant difference in the level of CEA between before and after treatment (P> 0.05) and the level of serum CA153 (P <0.05). Conclusion: Fuzheng Mixture combined with chemotherapy in the treatment of advanced triple-negative breast cancer can play a synergistic and attenuated role.